Ermenegildo Zegna NV
ZGN
DexCom
DXCM
New Fortress Energy
NFE
Workday
WDAY
eBay
EBAY
US Stock MarketDetailed Quotes
AFMD Affimed NV
- 1.1900
- +0.0100+0.85%
Close Dec 20 16:00 ET
- 1.2300
- +0.0400+3.36%
Post 20:01 ET
19.51MMarket Cap-0.25P/E (TTM)
1.2500High1.1438Low419.31KVolume1.1800Open1.1800Pre Close501.10KTurnover2.88%Turnover RatioLossP/E (Static)16.39MShares8.950052wk High1.09P/B17.32MFloat Cap1.143852wk Low--Dividend TTM14.55MShs Float242.0000Historical High--Div YieldTTM9.00%Amplitude1.1430Historical Low1.1950Avg Price1Lot Size
Affimed NV Stock Forum
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
▪️AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients
▪️AFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infusion related reactions (IRRs) were the main related side effect...
🤔
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Positive
High overall response rate of 86% in heavily pretreated patients
Complete response rate of 55% in patients with treatment options
Well-managed safety profile with no unexpected safety signals
Successful validation of treatment in multi-center setting
Negative
None.
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announc...
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Sunday, 8th December at 12:00 pm
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments
The combination showed a well-managea...
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Thursday, 5th December at 6:30 am
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
MANNHEIM, Germany, Dec. 05, 2024 (GLOBE NEWSWIRE) ...
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
-- LuminICE-203: Efficacy update of cohorts 1-4 expected to be presented at
a future scientific conference in Q4 2024.
-- AFM24-102: ORR and safety data from the EGFRwt cohort in Q4 2024.
-- AFM28-101: Data from the study is expected to be presented at a
scientific conference in Q4 2024.
-- AMF24-102: Mature PFS data from EGFRmut and EGFRwt cohorts expected to be
presented at a future conference in H1...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
• ORR and PFS data from the 25 patients in the EGFRmut cohort of the AFM24-102 study in Q3 2024.
• ORR and PFS data from the 40 patients in the EGFRwt cohort of the AFM24-102 study in Q4 2024.
No comment yet